Conference Call with Symphony Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Consumer Electronics company Symphony announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations: Rs 488 crore compared to Rs 332 crore during Q4FY24, change 47%. EBITDA: Rs 103 crore compared to Rs 59 crore during Q4FY24, change 77%. EBITDA margin: 21.22% for Q4FY25. PAT: Rs 79 crore compared to Rs 48 crore during Q4FY24, change 63%. FY25 Financial Highlights: Revenue from Operations: Rs 1,576 crore compared to Rs 1,156 crore during FY24, change 36%. EBITDA: Rs 316 crore compared to Rs 173 crore during FY24, change 83%. EBITDA margin: 20.05% for FY25. PAT: Rs 213 crore compared to Rs 148 crore during FY24, change 44%. Nrupesh Shah, Managing Director (Corporate Affairs), Symphony, said: Consolidated Performance: Our company has achieved significant milestones in the fiscal year 2025. We surpassed an annual revenue of Rs 1,500 crore, reaching Rs 1,576 crore (growth of 36%) and marked the highest ever March quarter revenue, a 47% increase compared to the same period last year. We also recorded the highest annual and quarterly EBITDA and PAT. Standalone Performance: In stand-alone performance, we crossed the Rs 1,000 crore annual revenue mark, achieving Rs 1,182 crore, a 49% YoY increase. Similar to our consolidated results, we recorded the highest March quarter revenue coupled with highest ever annual and quarterly EBITDA and PBT (before exceptional items). EBITDA margin expanded by 512 basis points at the consolidated level and 404 basis points at the stand-alone level, driven by the successful launch of 17 new air cooler models, gross margin expansion, economies of scale, operating leverage, diverse sales channels, and better penetration in semi-urban and rural areas etc. Pathway Update: We secured Power of Attorneys (POAs) and executed Equitable Mortgage Documents for 13 immovable properties in and around Delhi, NCR (land parcels, residential and commercial properties) of Pathways, its promoters and associates. These updates are in continuation of our previous communications dated February 18, 2025, February 5, 2025 and October 29, 2024. Subsidiaries’ performance: GSK, China demonstrated robust financial performance both domestically and internationally. Notably, it repaid a loan of Rs 13.5 crore to Symphony India from internal accruals, reducing the outstanding balance to Rs 49.6 crore. It has also entered into a Technology Transfer Agreement with IMPCO Mexico, valued at approximately USD 5 million (Rs 43.5 crore). We also written back 9.28 crore impairment provisions earlier made towards equity investment and loan in GSK, China due to its strong financial performance, cash flow, and profitability. In Brazil, our trading subsidiary continued to perform well, benefiting from strategic expansion in one of the world's largest air-cooler markets. IMPCO Mexico is witnessing consistent financial growth through broader product offerings and wider distribution reach. The Technology Transfer Agreement with GSK China is poised to further expand our leadership in the plastic air cooler market in Mexico. Our Australian subsidiary, CT, reversed an 11-quarter trend of year-on-year revenue decline, starting in the June 2022 quarter. This positive momentum is attributed to an expanded product portfolio, broader geographical and distribution reach, and cost optimization efforts. In compliance with Ind-AS, we made an impairment provision of Rs 50.15 crore for our equity investment in Symphony AU (CT), which is non-cash in nature and does not impact ongoing operations or the future roadmap. Result PDF
Conference Call with Symphony Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.